摘要
目的比较头孢西丁钠和头孢吡肟治疗老年支气管肺炎的临床疗效与安全性。方法将186例老年支气管肺炎患者随机分为3组,观察组给予头孢西丁钠或头孢吡肟治疗,对照组给予阿奇霉素治疗,3组疗程均为2周。结果总有效率头孢西丁钠组为82.26%,头孢吡肟组为95.16%,阿奇霉素组为87.10%,3组总有效率的差异有统计学意义(P<0.05)。头孢西丁钠组、头孢吡肟组和阿奇霉素组不良反应发生率分别为9.68%,3.23%和4.84%,头孢西丁钠组与后两组的差异有统计学意义(P<0.05),头孢吡肟组与阿奇霉素组的差异无统计学意义(P>0.05)。结论头孢吡肟治疗老年支气管肺炎的疗效较头孢西丁钠更好,不良反应发生率更低,值得临床进一步研究。
Objective To compare the clinical efficacy and safety of cefoxitin sodium and cefepime in treating of senile bronchopneumonia. Methods 186 patients with senile bronchopneumonia were randomly divided into three groups. The two observation groups were given cefoxitin sodium and cefepime respectively. The control group was treated by azithromycin. The course of treatment was 2 weeks treated. Results The total effective rate was 82. 26% in the cefoxitin sodium group,95. 16% in the cefepime group and 87. 10% in the azithromycin group respectively,the differences among 3 groups had statistical significance（P〈0. 05）. The occurrence rates of ADR in cefoxitin sodium group,cefepime group,and azithromycin group were 9. 68%,3. 23 % and 4. 84% respectively,there was statistically significant difference between the cefoxitin sodium group with the other two groups（P〈0. 05）,the difference between the cefepime group and the azithromycin group had no statistical significance（P〉0. 05）. Conclusion Cefepime has much better clinical efficacy and safety than cefoxitin sodium in treating senile bronchopneumonia,which is worthy of further clinical research.
出处
《中国药业》
CAS
2014年第24期42-43,共2页
China Pharmaceuticals
关键词
支气管肺炎
疗效
不良反应
头孢西丁钠
头孢吡肟
bronchopneumonia
curative efficacy
adverse reaction
cefoxitin sodium
cefepime
